HLX43 is a next-generation anti–PD-L1 ADC designed to combine immune checkpoint blockade with the potent cytotoxic activity of a topoisomerase inhibitor payload, positioning it as a potentially best-in-class and best-in-disease therapy. At ASCO 2026, data across multiple tumor types, including NSCLC and nasopharyngeal carcinoma (NPC), further highlighted its potential as a biomarker-independent treatment approach. In recurrent/metastatic NPC, HLX43 demonstrated encouraging efficacy and a manageable safety profile in heavily pretreated patients who had progressed following second-line or later chemotherapy and PD-(L)1 inhibitor therapy, supporting its continued clinical development.

These findings strengthen HLX43's position as a promising emerging anti–PD-L1 ADC with the potential to address significant unmet needs across multiple cancers. As Henlius advances its global development strategy, ongoing studies spanning China, the United States, Europe, Japan, and Australia are expected to further define HLX43's role in the evolving oncology landscape.

KOL insights

“HLX43 is a potentially best-in-class pan-tumor ADC candidate targeting PD-L1, which exhibits dual mechanisms integrating immune checkpoint blockade and payload-mediated cytotoxicity. Currently, it has demonstrated a manageable safety profile and encouraging efficacy in various solid tumor.”–Expert Opinion

“HLX43 delivered meaningful clinical responses and manageable toxicity in heavily pretreated r/m NPC patients, reinforcing its promise as an emerging anti–PD-L1 ADC in this challenging treatment setting.”– Expert Opinion

Conclusion

HLX43 is emerging as a promising anti–PD-L1 ADC in the treatment of recurrent/metastatic nasopharyngeal carcinoma, demonstrating encouraging efficacy and a manageable safety profile in heavily pretreated patients who had progressed following chemotherapy and PD-(L)1 inhibitor therapy. Its dual mechanism, combining immune checkpoint blockade with a topoisomerase inhibitor payload, offers a differentiated approach that may help address treatment resistance and broaden patient eligibility regardless of biomarker status.

The therapy enters a competitive landscape that includes established PD-1 inhibitors and a growing pipeline of ADCs and novel immunotherapy combinations. However, HLX43's biomarker-independent activity and ADC-based design could provide a distinct advantage in the later-line setting. Strategically, Henlius is positioning HLX43 as a broad-spectrum oncology asset, advancing global clinical development across NPC, NSCLC, and other solid tumors to maximize its commercial and clinical potential.